Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics presents a classic biotech dilemma: a pristine balance sheet masking a lack of profitability and a volatile price history. The company holds a fortress-like liquidity position with massive cash reserves and negligible debt, which is a rare and valuable trait in the sector. However, the stock has failed to translate this financial safety into consistent share price appreciation, trading well below its 52-week highs despite a recent year-over-year surge. The recent capital raise indicates management is prioritizing runway extension over immediate shareholder returns, a common strategy for pre-revenue companies but one that suppresses valuation multiples. From a short-term perspective, the technicals are mixed; the stock is hovering near its 50-day average, suggesting indecision rather than a clear breakout. The options market reinforces this caution, with traders loading up on cheap, deep out-of-the-money puts, betting on a potential clinical miss or regulatory hurdle that could drag the price down further. While the fundamentals are not broken—indeed, the cash pile is substantial—the absence of commercial revenue and the history of erratic performance make this a speculative hold rather than a conviction buy. Investors here are paying for a lottery ticket on a drug pipeline, not a business with predictable cash flows.